Clinical Trials & Research

Reviewed by Emily Henderson, B.Sc.Oct 30 2020 The same biochemical triggers that spur a “fight or flight” response when we encounter threats may help tumor cells to thrive. A team of researchers from Roswell Park Comprehensive Cancer Center is looking at ways to disrupt that dynamic so that cancer treatments can be more effective. Their
0 Comments
SARASOTA, Fla. and NOVATO, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) — GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of intrathecally administered GTX-102, an investigational treatment for Angelman syndrome, today announced positive interim data from the Phase 1/2 study of GTX-102. Preliminary results from the first five patients treated
0 Comments
Nations around the world have enacted unprecedented travel restrictions and lockdowns in response to the coronavirus disease 2019 (COVID-19) pandemic. These measures ranged from movement restrictions on a local level to regional and international travel restrictions. These restrictions are put in place to contain the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
0 Comments
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 26, 2020– Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a supply agreement with the Ministry of Public Health of Qatar for mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support the Ministry’s ongoing efforts to secure early
0 Comments
A recent study published on the preprint server bioRxiv* in October 2020 reports the development of a novel vaccine based on a simian adenoviral vector obtained from a group C gorilla isolate called GRAd32. This could help speed up vaccine development. Low Seroprevalence for Simian Adenoviruses Simian adenoviruses are isolated from non-human primates like the
0 Comments
KENILWORTH, N.J.–(BUSINESS WIRE) October 20, 2020 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from two additional Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine. In the PNEU-PATH (V114-016) study, healthy adults 50 years of age or
0 Comments
21 October 2020 — ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinical development programme. In the midst of the global pandemic, the analysis found
0 Comments
Sudden loss of smell (anosmia) and taste (ageusia) are becoming increasingly common symptoms of coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the agent responsible for the COVID-19 pandemic that started in December 2019. The virus causes atypical and severe pneumonia in infected individuals, with symptoms ranging from asymptomatic and mild
0 Comments
October 16, 2020 — The National Institutes of Health has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which the immune system unleashes excessive amounts of proteins that trigger inflammation — called
0 Comments
The COVID-19 pandemic has led to intensive scientific efforts to bring about an effective vaccine for global distribution. Many different vaccine design approaches are underway. A recent study published in the journal The Lancet Infectious Diseases in October 2020 reports a potentially successful inactivated virus vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The
0 Comments
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) – Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that the first subject has been dosed in its Phase 1 study of VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate. “We are advancing VXA-CoV2-1 into clinical development
0 Comments
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 13, 2020– Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s vaccine candidate against COVID-19. This initiation follows positive results from a preclinical viral challenge study of
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 15 2020 The development of cancer is a highly complicated process, involving multiple genes and signaling pathways that become upregulated or downregulated throughout different stages of tumor growth and spread. Two of the most commonly altered genes in cancer are p53 and AKT. In a new article published in the
0 Comments
October 13, 2020 — The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today launched a study designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and merit advancement into larger clinical trials. The ACTIV-5 Big Effect Trial, which
0 Comments
NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced it has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding the Company’s New Drug Application (“NDA”) for IV
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 9 2020 Rural emergency departments often lack the medical specialists who staff larger, urban hospitals. Yet rural patients have the same conditions–and need the same prompt care–that people in cities do. West Virginia University researcher Scott Findley has received a $1.2 million grant from the Health Resources and Services Administration–a
0 Comments
NEW YORK and MAINZ, GERMANY, October 6, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lead candidate from the companies’ vaccine development program against COVID-19. The EMA’s decision to start a rolling review follows the encouraging preliminary
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 9 2020 Dr. Katherine Pannel was initially thrilled to see President Donald Trump’s physician is a doctor of osteopathic medicine. A practicing D.O. herself, she loved seeing another glass ceiling broken for the type of doctor representing 11% of practicing physicians in the U.S. and now 1 in 4 medical
0 Comments
NEW YORK & BRISBANE, Calif.–(BUSINESS WIRE) October 07, 2020 — Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients. AFFINE is a global
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 7 2020 There is great potential in gene therapy for treating certain types of cancer and genetic defects, immunological diseases, wounds and infections. The therapies work by delivering genes into the patients’ cells, which then produce therapeutic proteins to treat the affliction. When determining the method of delivery for these
0 Comments
THOUSAND OAKS, Calif., Oct. 5, 2020 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 126 patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC), who had failed a median of two prior lines of anti-cancer therapies (immunotherapy and/or chemotherapy). Sotorasib demonstrated an
0 Comments
Print this page PLYMOUTH MEETING, Pa., Sept. 28, 2020 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has notified the company it has additional questions about the company’s
0 Comments
Oct 2 2020 Global glass primary packaging supplier SGD Pharma has expanded its ready-to-use (RTU) molded glass vial range to introduce a market-first 50ml volume option in tray developed at industrial scale by a molded glass manufacturer. The Sterinity platform, which includes both ISO and EasyLyo injectable vials, offers high-quality sterile Type I molded glass
0 Comments